CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 28 enrolled
Drug / intervention
MAA868 Cohort 1 +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04213807
NCT04213807Phase 2Completed
CompareCT.gov

A Randomized, Placebo-controlled, Dose-range Finding Study to Assess the Pharmacokinetic and Pharmacodynamic Parameters, Safety, Tolerability, and Immunogenicity of MAA868 in Patients With Atrial Fibrillation

Anthos Therapeutics, Inc.·interventional·Posted Dec 30, 2019·Updated Jan 11, 2022

In Brief

A Phase 2 clinical trial evaluating MAA868 Cohort 1, MAA868 Cohort 2, and 2 other interventions for Atrial Fibrillation. Completed, enrolled 28 participants across 6 sites.

Detailed Summary

This study is a multicenter, randomized, subject and Investigator-blinded, placebo-controlled, parallel-group, multiple ascending dose-ranging study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) effects of MAA868 in patients with atrial fibrillation (AF) or flutter at low risk of thromboembolic stroke or peripheral embolism.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
CountriesUnited States
CollaboratorsCovance

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedDec 30, 2019
Enrollment StartDec 11, 2019
Primary CompletionDec 29, 2020
Study CompletionMar 8, 2021
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 6.5 years ago

Interventions

MAA868 Cohort 1biological

Subcutaneous injection: low dose

MAA868 Cohort 2biological

Subcutaneous injection: high dose

MAA868 Cohort 3biological

Subcutaneous injection: Dose to be determined.

Placeboother

Subcutaneous injection: Placebo